Tilray: Cantor Lowers Price Target, Walks Back Coca-Cola Comments

Last week, Cantor Fitzgerald updated their estimates on a bundle of Canadian License Producers. In every case, they slashed the 3 largest license producers’ price targets. Cantor Fitzgerald lowered their 12-month price target on Tilray Inc (TSX: TLRY) (NASDAQ: TLRY) to C$18 from C$19 and reiterated their overweight rating.

Tilray currently has 20 analysts covering the stock with an average 12-month price target of $16.57 or a 4% upside. Out of the 20 analysts, 2 have strong buys, 3 have buys, 13 have hold ratings and 2 have sell ratings. The street high sits at $27 while the lowest comes in at $1.27.

Cantor Fitzgerald says they are lowering their price target and reducing their 2021 estimates but raising their 2022 estimates. For 2021, they believe that Canada is still facing a slower ramp-up than during the pandemic and that COVID-19 headwinds will continue to impact their ancillary businesses.

With the recent approval of Tilray issuing new shares, Cantor believes Tilray will go on a shopping spree to continue to build up their option agreements in the U.S. They believe this will have to happen, as management has guided for $4 billion in top-line revenue by 2024. They also walk back their recent comment about Tilray being the next Coca-Cola, saying that the comment was pre-mature, but “only a few companies are on that trajectory, and we could put TLRY in that group.”

Cantor, in another paragraph, talks about what they believe will drive stock performance. They say that historically, it’s been investors’ outlook for U.S federal level reform/legalization. But they believe that, for the Canadian producers, “credible vision articulation” will be the key driver of stock performance.

Below you can see Cantor’s updated 2021 and 2022 estimates.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Why the Market May Be Misreading Iran | David Woo

Why US Fertilizer Supply Could Matter a Lot More Now | Pat Varas – Sage Potash

Roscan Gold: Mali Discount Hits Kandiole PEA

Recommended

Antimony Resources Begins Technical Studies For Permitting Bald Hill Antimony Project

First Majestic Aims To Restart Production At Jerritt Canyon In H2 2027

Related News

Haywood Reiterates $80 Price Target On Trulieve After Harvest Health Purchase

On October 1st, Trulieve Cannabis (CSE: TRUL) announced that they completed their $1.75 billion acquisition...

Monday, October 11, 2021, 04:43:00 PM

Medipharm Labs: Canaccord Lowers Targets After Earnings

On August 16, Medipharm Labs (TSX: LABS) reported their second quarter financial results. The company...

Friday, August 20, 2021, 07:54:00 AM

Hexo To Be Acquired By Tilray For US$56.0 Million

It appears that Sebastian St-Louis’s “billion dollar start-up” has finally been sold. Hexo Corp (TSX:...

Monday, April 10, 2023, 05:26:52 PM

Nutrien Sees Consensus Price Target Improvement Following Raised Guidance

On June 21st, Nutrien (TSX: NTR) raised their first half 2021 earnings per share guidance...

Wednesday, June 23, 2021, 03:36:00 PM

Stifel: Comparing US Cannabis To Traditional CPG Suggests ~20x Upside

On Monday Stifel GMP released their 2021 US Cannabis outlook. Andrew Partheniou, Stifel GMP’s cannabis...

Wednesday, January 6, 2021, 10:48:00 AM